RAN-MEMANTINE TABLET

Nazione: Canada

Lingua: inglese

Fonte: Health Canada

Principio attivo:

MEMANTINE HYDROCHLORIDE

Commercializzato da:

RANBAXY PHARMACEUTICALS CANADA INC.

Codice ATC:

N06DX01

INN (Nome Internazionale):

MEMANTINE

Dosaggio:

10MG

Forma farmaceutica:

TABLET

Composizione:

MEMANTINE HYDROCHLORIDE 10MG

Via di somministrazione:

ORAL

Confezione:

30/100

Tipo di ricetta:

Prescription

Area terapeutica:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Dettagli prodotto:

Active ingredient group (AIG) number: 0150423001; AHFS:

Stato dell'autorizzazione:

APPROVED

Data dell'autorizzazione:

2014-02-27

Scheda tecnica

1
PRODUCT MONOGRAPH
Pr
RAN
™
-MEMANTINE
Memantine Hydrochloride Tablets
10 mg
N-methyl-D-aspartate (NMDA) receptor antagonist
Ranbaxy Pharmaceuticals Canada Inc.,
2680 Matheson Blvd. E., Suite 200
Mississauga, Ontario
L4W 0A5
Date of revision:
July 24, 2015
Control No. 186301
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
2
NAME OF DRUG
Pr
RAN
™
-MEMANTINE
Memantine Hydrochloride Tablets
10 mg
THERAPEUTIC CLASSIFICATION
N-methyl-D-aspartate (NMDA) receptor antagonist
ACTION AND CLINICAL PHARMACOLOGY
Persistent activation of the central nervous system
N-methyl-D-aspartate (NMDA) receptors by
the excitatory amino acid glutamate has been hypothesized to
contribute to the symptomatology
of Alzheimer’s disease. Memantine is postulated to exert its
therapeutic effect through its action
as a low to moderate affinity uncompetitive (open channel) NMDA
receptor antagonist, which
binds preferentially to the NMDA receptor-operated cation channels. It
blocks the effects of
pathologically elevated sustained levels of glutamate that may lead to
neuronal dysfunction.
There is no clinical evidence that memantine prevents or slows
neurodegeneration or alters the
course of the underlying dementing process in patients with
Alzheimer’s disease. Memantine
exhibits low to negligible affinity for other receptors (GABA,
benzodiazepine, dopamine,
adrenergic, noradrenergic, histamine and glycine) or voltage-dependent
Ca
2+
, Na
+
or K
+
channels. In addition, it does not directly affect the acetylcholine
receptor or cholinergic
transmission, which have been implicated in the cholinomimetic side
effects (e.g., increased
gastric acid secretion, nausea and vomiting) seen with
acetylcholinesterase inhibitors.
Memantine showed antagonist effects at the 5HT
3
receptor with a potency similar to that for the
NMDA receptor.
In vitro studies have shown that memantine does not affect the
reversible inhibition of
acetylcholinesterase by donepezil or galantamine.
PHARMACOKINETICS
ABSORPTION
Orally administered memantine is completely